Copyright
©The Author(s) 2023.
World J Clin Cases. Nov 16, 2023; 11(32): 7795-7805
Published online Nov 16, 2023. doi: 10.12998/wjcc.v11.i32.7795
Published online Nov 16, 2023. doi: 10.12998/wjcc.v11.i32.7795
Variable | Univariate analysis | Multivariate analysis | ||
HR (95%CI) | P value | HR (95%CI) | P value | |
Overall survival | ||||
Group | ||||
LG | 1 (reference) | 1 (reference) | ||
OG | 1.28 (0.67-2.45) | 0.46 | 1.24 (0.64-2.40) | 0.52 |
Age | ||||
≤ 60 | 1 (reference) | 1 (reference) | ||
> 60 | 1.35 (0.72-2.54) | 0.35 | 1.32 (0.69-2.51) | 0.40 |
Sex | ||||
Male | 1 (reference) | 1 (reference) | ||
Female | 0.86 (0.45-1.64) | 0.65 | 0.84 (0.43-1.61) | 0.59 |
BMI | ||||
≤ 25 | 1 (reference) | 1 (reference) | ||
> 25 | 1.12 (0.58-2.16) | 0.74 | 1.09 (0.56-2.13) | 0.79 |
Tumor location | ||||
Upper third | 1 (reference) | 1 (reference) | ||
Middle third | 0.97 (0.47-2.01) | 0.94 | 0.95 (0.45-1.98) | 0.89 |
Lower third | 0.92 (0.44-1.91) | 0.82 | 0.89 (0.42-1.86) | 0.75 |
Tumor size | ||||
≤ 5 cm | 1 (reference) | 1 (reference) | ||
> 5 cm | 1.41 (0.75-2.65) | 0.28 | 1.38 (0.72-2.62) | 0.32 |
Pathological stage1 | ||||
II | 1 (reference) | 1 (reference) | ||
III | 2.15 (1.12-4.13) | 0.02 | 2.12 (1.09-4.10) | 0.03 |
Pathological response2 | ||||
Complete | 1 (reference) | 1 (reference) | ||
Partial | 1.22 (0.38-3.94) | 0.74 | 1.18 (0.36-3.86) | 0.79 |
Stable | 1.45 (0.45-4.66) | 0.54 | 1.41 (0.43-4.59) | 0.57 |
Progressive | 2.67 (0.81-8.80) | 0.11 | 2.61 (0.78-8.68) | 0.12 |
Disease-free survival | ||||
Group | ||||
LG | 1 (reference) | 1 (reference) | ||
OG | 1.19 (0.64-2.21) | 0.58 | 1.16 (0.62-2.17) | 0.64 |
Age | ||||
≤ 60 | 1 (reference) | 1 (reference) | ||
> 60 | 1.25 (0.68-2.30) | 0.47 | 1.23 (0.66-2.27) | 0.51 |
Sex | ||||
Male | 1 (reference) | 1 (reference) | ||
Female | 0.91 (0.49-1.70) | 0.77 | 0.89 (0.47-1.66) | 0.71 |
BMI | ||||
≤ 25 | 1 (reference) | 1 (reference) | ||
> 25 | 1.08 (0.57-2.05) | 0.81 | 1.05 (0.54-2.01) | 0.88 |
Tumor location | ||||
Upper third | 1 (reference) | 1 (reference) | ||
Middle third | 0.99 (0.49-2.02) | 0.98 | 0.97 (0.47-1.99) | 0.93 |
Lower third | 0.94 (0.46-1.93) | 0.87 | 0.91 (0.44-1.88) | 0.80 |
Tumor size | ||||
≤ 5 cm | 1 (reference) | 1 (reference) | ||
> 5 cm | 1.32 (0.72-2.42) | 0.37 | 1.29 (0.69-2.38) | 0.42 |
Pathological stage | ||||
II | 1 (reference) | 1 (reference) | ||
III | 2.03 (1.08-3.81) | 0.03 | 2.01 (1.06-3.78) | 0.03 |
Pathological response | ||||
Complete | 1 (reference) | 1 (reference) | ||
Partial | 1.18 (0.38-3.67) | 0.78 | 1.15 (0.36-3.59) | 0.82 |
Stable | 1.36 (0.43-4.30) | 0.60 | 1.32 (0.41-4.23) | 0.64 |
Progressive | 2.49 (0.77-8.07 | 0.13 | 2.43 (0.74-7.97) | 0.14 |
- Citation: Yu CD, Zhang K. Efficacy and safety of laparoscopic vs open gastrectomy after neoadjuvant therapy for locally advanced gastric cancer. World J Clin Cases 2023; 11(32): 7795-7805
- URL: https://www.wjgnet.com/2307-8960/full/v11/i32/7795.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i32.7795